Alirocumab

Alirocumab is a human monoclonal antibody directed at proprotein convertase subtilisin kexin type 9 (PCSK9) and has been shown to reduce low-density lipoprotein (LDL) cholesterol levels.

What can Sanquin do for you?

Measure drug levels of free drug in the serum using an validated ELISA.
Measure the immunogenicity of alirocumab.
Provide assay reagents or co-develop novel testing strategies.
Folllowing ISO, FDA/EMA, RUO guidelines.

Enquire about our drug level and ADA assays by emailing us at [email protected].

Last edited on: 23 November 2022